Intuitive Surgical (ISRG) Expected to Announce Quarterly Earnings on Tuesday

Intuitive Surgical (NASDAQ:ISRG) is expected to post its quarterly earnings results after the market closes on Tuesday, April 22nd. Analysts expect Intuitive Surgical to post earnings of $1.71 per share and revenue of $2.19 billion for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $490.13 on Tuesday. Intuitive Surgical has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The stock has a market cap of $174.57 billion, a PE ratio of 76.46, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. The stock has a fifty day moving average of $530.71 and a 200-day moving average of $532.76.

Analysts Set New Price Targets

ISRG has been the topic of a number of recent analyst reports. Citigroup increased their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Robert W. Baird decreased their price target on shares of Intuitive Surgical from $707.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, March 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Truist Financial cut their price objective on Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a report on Monday, March 17th. Finally, Wells Fargo & Company lifted their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $611.86.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 11,545 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the transaction, the executive vice president now directly owns 5,224 shares of the company’s stock, valued at approximately $2,607,925.28. The trade was a 68.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brian Edward Miller sold 8,900 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the sale, the executive vice president now directly owns 5,758 shares of the company’s stock, valued at $2,793,033.06. The trade was a 60.72 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,754 shares of company stock worth $17,691,621. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

An institutional investor recently raised its position in Intuitive Surgical stock. Brighton Jones LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 24.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,672 shares of the medical equipment provider’s stock after acquiring an additional 731 shares during the period. Brighton Jones LLC’s holdings in Intuitive Surgical were worth $1,916,000 at the end of the most recent reporting period. Institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.